

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 18 July 2000 (18.07.00)	
<b>International application No.</b> PCT/EP99/09036	<b>Applicant's or agent's file reference</b> B0019WO
<b>International filing date</b> (day/month/year) 23 November 1999 (23.11.99)	<b>Priority date</b> (day/month/year) 24 November 1998 (24.11.98)
<b>Applicant</b> RAPOSO, Graça et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

20 May 2000 (20.05.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland	<b>Authorized officer</b> F. Baechler
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>B0019W0</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/EP 99/ 09036</b>	International filing date (day/month/year) <b>23/11/1999</b>	(Earliest) Priority Date (day/month/year) <b>24/11/1998</b>
Applicant <b>INSTITUT NATIONAL DE LA SANTE ET DE LA REC..et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 99/09036

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 8-11, 13, 14, 16 and 17 (all partly)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 8-11, 13, 14, 16 and 17 (all partly)

A meaningful search could not be carried out on the basis of claims 8-11, 13, 14, 16 and 17 as such, as their subject-matter is too vaguely and indefinitely defined due to the use of an imprecise wording. Nevertheless, a search has been carried out on the basis of the said claims assuming that the (i) claimed compositions were compositions for regulating the immune response (see description page 2, lines 1-19), and (ii) the molecule, antigen and polypeptide referred to in claims 8, 11 and 13, respectively, were to be delivered to dendritic cells (see description page 10, lines 8-14).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/09036

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 A61K38/17 C07K19/00 C12N1/21 C12N7/01  
C12N15/12 A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, STRAND, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GIUFFRIDA ET AL: "Isolation and characterization of full and truncated forms of human breast carcinoma protein BA46 from human milk fat globule membranes"</p> <p>JOURNAL OF PROTEIN CHEMISTRY, XX, XX, vol. 17, no. 2, February 1998 (1998-02), pages 143-148, XP002101999</p> <p>ISSN: 0277-8033</p> <p>page 143, left-hand column, paragraph 1</p> <p>page 144, left-hand column, paragraph 1</p> <p>page 145, right-hand column</p> <p>figure 3</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 September 2000

Date of mailing of the international search report

16. 10. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mennessier, T

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/09036

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 15171 A (CANCER RES FUND OF CONTRACOSTA) 8 June 1995 (1995-06-08) page 6 page 7 page 14, line 20 -page 15, line 2 page 24, line 19 -page 25, line 3 claims 1,6,7,11,24	12-14
X	US 5 455 031 A (CERIANI ROBERTO L ET AL) 3 October 1995 (1995-10-03) column 7, line 35-67 column 8, line 1-54 column 10, line 18-56 column 16, line 41 -column 17, line 13	12-14
A	TAYLOR M R ET AL: "Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion" DNA AND CELL BIOLOGY,US,NEW YORK, NY, vol. 16, no. 7, July 1997 (1997-07), pages 861-869, XP002102000 ISSN: 1044-5498 the whole document	1-19
A	COUTO ET AL: "Cloning and sequence analysis of human breast epithelial antigen BA46 reveals an RGD cell adhesion sequence presented on an epidermal growth factor-like domain" DNA AND CELL BIOLOGY,US,NEW YORK, NY, vol. 15, no. 4, 1996, pages 281-286, XP002102001 ISSN: 1044-5498 the whole document	1-19

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/09036

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9515171 A	08-06-1995	US 5972337 A	26-10-1999
		CA 2177991 A	08-06-1995
		EP 0735891 A	09-10-1996
		JP 9510082 T	14-10-1997
US 5455031 A	03-10-1995	AU 9057091 A	26-05-1992
		CA 2095330 A	02-05-1992
		EP 0555397 A	18-08-1993
		JP 6510981 T	08-12-1994
		WO 9207939 A	14-05-1992
		US 5972337 A	26-10-1999

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 07 MAR 2001

WIPO

PCT

Applicant's or agent's file reference B0019WO		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP99/09036	International filing date (day/month/year) 23/11/1999	Priority date (day/month/year) 24/11/1998	
International Patent Classification (IPC) or national classification and IPC A61K38/00			
Applicant INSTITUT NATIONAL DE LA SANTE ET DE LA REC..et al.			

RECEIVED

MAY 02 2001



TECH CENTER 1600/2900

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 8 sheets, including this cover sheet.
  - ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 2 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 20/05/2000	Date of completion of this report 02.03.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Mennessier, T Telephone No. +49 89 2399 8687 



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP99/09036

**I. Basis of the report**

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*

**Description, pages:**

1-30 as originally filed

**Claims, No.:**

1-19 with telefax of 19/02/2001

**Drawings, sheets:**

1/5-5/5 as originally filed

**Sequence listing part of the description, pages:**

1-11, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP99/09036

- ☐ the description,      pages:  
☐ the claims,      Nos.:  
☐ the drawings,      sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:  
**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.  
☒ claims Nos. 8-11,13-19.

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
- ☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 8-11,13-19 are so unclear that no meaningful opinion could be formed (*specify*):  
**see separate sheet**
- ☒ the claims, or said claims Nos. 8-11,13-19 are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.  
☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/09036

## 1. Statement

Novelty (N)	Yes:	Claims	1-7
	No:	Claims	12
Inventive step (IS)	Yes:	Claims	1-7
	No:	Claims	12
Industrial applicability (IA)	Yes:	Claims	1-7,12
	No:	Claims	

## 2. Citations and explanations **see separate sheet**

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

1. Comments with respect to item III

- (i) The subject-matter of **claims 8-11 and 13-19** is defined using a wording which is so imprecise that it **lacks both clarity and support in the description.**
- (ii) More particularly, **claims 8-10 and 16** are each directed to a "*composition*" the nature of which has not been specified and cannot be inferred from the wording of the claims.
- (iii) Vague terms such as "*molecule*" (see **claims 8-10**) or "*polypeptide*" (see **claims 13 and 14** [as the subject-matter of this claim is defined with a back-reference to claim 13]) are used.
- (iv) Moreover, an actual support in the description, i.e., a support which would permit an accurate assessment of inventive step does not exist for the subject-matter of **claims 8-11 and 13-19** which extends beyond the true contribution to the state of art of the invention, based on the findings - which mark lactadherin as a compound efficient at regulating the immune response - that lactadherin is produced by dendritic cells exposed at the surface of antigens vesicles, functions as an adaptor in cross- presentation to CTLs and interacts with particulate antigens, through the phospholipid binding sites, and with dendritic cells, through the RGD domains, and therefore mediates the phagocytosis of said particular antigens.
- (v) In this last respect, **claims 18 and 19** feature inventions which are regarded as essentially speculative, **in the absence of any experimental illustration in the description whereas the technical field of the invention is one which requires experimental proof,** that a pharmaceutical composition containing the claimed recombinant virus or cell would be efficient at regulating the immune response.
- (vi) The IPEA would like to stress the point that the terms of a claim should, as far as possible, be clear for the person skilled in the art from the wording of the claim **alone**, which appears not to be the case of **claims 8-10, 13, 14 and 16** as explained at points (ii) and (iii) above.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP99/09036

2. Comments with respect to item V

a) Claims 1-7

(i) Novelty (Article 33(2) PCT)

The use of lactadherin or a variant thereof for the preparation of a composition for regulating the immune response appears not to be disclosed in the state of the art. Therefore, the subject-matter of claims 1-7 may be regarded as new.

(ii) Inventive step (Article 33(3) EPC)

It can be considered that the identification of lactadherin as a compound that mediates the interaction between particulate antigens and dendritic cells and functions as an adaptor of cross-priming could not have been predicted by a person skilled in the art aware of the cited state of the art. Consequently, the subject-matter of claims 1-7 which permits to either reduce the immune response or facilitate an immune response against a desired antigen appears to solve in a non-obviously manner the technical problem posed by the provision of means which are capable of regulating the immune response. Therefore, it is concluded that the said subject-matter of claims 1-7 may be considered to involve an inventive step.

(iii) Industrial applicability (Article 33(4) PCT)

For the assessment of the present **claims 1-7** the Applicants are reminded that on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture

of a medicament for a new medical treatment.

b) Claim 12

(i) Documents cited

Reference is made to the following documents which are cited in the international search report:

- \* D1: *J. Protein Chem.*, 17(2), February 1998, 143-8
- \* D2: US-A-5 455 031
- \* D3: WO 95/15171

(ii) Novelty (Article 33(2) PCT)

Each of documents D1, D2 and D3 discloses a variant of human lactadherin (= BA46) lacking a functional integrin binding site (see D1, page 45 which discloses a 30-kDa variant corresponding to the C-terminal 180 amino acids of BA46; D2, column 7, lines 41-55 which discloses a 25-kDa variant corresponding to the C-terminal 217 amino acids of BA46; and D3 which discloses a variant corresponding to the C-terminal 266 amino acids of BA46 and a variant corresponding to the C-terminal 216 amino acids of BA46 [see page 14, lines 31-32, together with sequences referred to as SEQ ID NO:6 and SEQ ID NO:3 on Tables 2 and 4]).

Therefore, as according to an aspect (the claimed variant being such that it only **optionally** lacks a functional integrin binding site), **claim 12** is directed to a variant which lacks a functional integrin binding site, the subject-matter of said claim lacks novelty.

(iii) Inventive step (Article 33(3) EPC)

As the subject-matter of **claim 12** lacks novelty, it also does not involve an inventive step.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP99/09036

3. Comments with respect to item VIII

In view of the remarks made at point 2 above, claims 8-11 and 13-19 are objected to under Article 6 PCT.

CLAIMS

1. The use of lactadherin or a variant thereof, for the preparation of a composition for regulating the immune response.
- 5        2. The use according to claim 1, for the inhibition of the cross-priming of antigens.
3. The use according to claim 2, of a variant of lactadherin lacking a functional phospholipid binding site and/or a functional integrin binding site.
- 10       4. The use according to claim 1, for the stimulation of the phagocytosis of antigens by dendritic cells.
5. The use according to claim 1, for the stimulation of the cross-priming of antigens.
- 15       6. The use of lactadherin or a variant thereof, for the preparation of a composition for the delivery of a molecule to a dendritic cell.
7. The use according to any one of the preceding claims, wherein the lactadherin or variant thereof is human lactadherin or a variant thereof.
- 20       8. A composition comprising lactadherin or a variant thereof in association with a molecule.
- 25       9. The composition of claim 8, wherein said molecule is covalently associated to the lactadherin or variant thereof.
10. The composition of claim 8, comprising a liposome, wherein the liposome comprises lactadherin or a variant thereof covalently associated to a molecule.
- 30



11. An immunogenic composition comprising lactadherin or a variant thereof in association with an antigen.

5 12. A variant of lactadherin, wherein said variant lacks a functional phospholipid binding site and, optionally, also lacks a functional integrin binding site.

10 13. A chimeric protein comprising lactadherin or a variant thereof fused to a polypeptide.

14. A nucleic acid encoding a protein as defined in claim 13.

15 15. A liposome comprising a recombinant lactadherin or variant thereof.

16 16. A composition comprising a variant of lactadherin according to claim 12 or a chimeric protein according to claim 13 or a liposome according to claim 15.

20 17. The composition of claim 11, wherein the antigen is a protein, polypeptide, peptide, virus or bacteria.

25 18. A recombinant virus expressing lactadherin as a surface molecule.

19. A recombinant cell expressing lactadherin as a surface molecule.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 38/00</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/30667</b> (43) International Publication Date: <b>2 June 2000 (02.06.00)</b>
<p>(21) International Application Number: <b>PCT/EP99/09036</b></p> <p>(22) International Filing Date: <b>23 November 1999 (23.11.99)</b></p> <p>(30) Priority Data: <b>98402925.6</b>                      <b>24 November 1998 (24.11.98)</b>      <b>EP</b></p> <p>(71) Applicants (<i>for all designated States except US</i>): <b>INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE [FR/FR]; 101, rue de Tolbiac, F-75654 Paris Cedex 13 (FR). INSTITUT CURIE [FR/FR]; 26, rue d'Ulm, F-75248 Paris Cedex 05 (FR). CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3, rue Michel-Ange, F-75794 Paris Cedex 16 (FR).</b></p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): <b>RAPOSO, Graça [PT/FR]; 8, rue Saint-Martin, F-75004 Paris (FR). THERY, Clotilde [FR/FR]; 6, rue des Quatre Vents, F-75006 Paris (FR). AMIGORENA, Sebastian [FR/FR]; 124, boulevard A. Blanqui, F-75013 Paris (FR).</b></p> <p>(74) Agent: <b>CABINET BECKER ET ASSOCIES; 10, rue de Milan, F-75009 Paris (FR).</b></p>		<p>(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: <b>COMPOSITIONS AND METHODS USING LACTADHERIN OR VARIANTS THEREOF</b></p> <p>(57) Abstract</p> <p>The present invention relates to novel methods and composition that can be used in the biological, experimental and medical areas. More particularly, the invention relates to compositions and methods using lactadherin or variants thereof, or a corresponding nucleic acid, for regulating (i.e., inducing, inhibiting, stimulating, etc.) or monitoring an immune response, more specifically a CTL response, as well as for the delivery of molecules to dendritic cells, in vitro, ex vivo or in vivo.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

COMPOSITIONS AND METHODS USING LACTADHERIN OR  
VARIANTS THEREOF

The present invention relates to novel methods and composition that can be used in the biological, experimental and medical areas. More particularly, the invention relates to compositions and methods for regulating (i.e., inducing, inhibiting, stimulating, etc.) or monitoring an immune response, more specifically a CTL response, as well as for the delivery of molecules to dendritic cells, in vitro, ex vivo or in vivo.

The invention also relates to novel proteins, nucleic acids and vectors, and their use in the above discussed areas, for instance for the cross-priming of antigens, the phagocytosis of molecules by dendritic cells, etc. The present invention also provides methods of screening of molecules capable of regulating the CTL response.

Antigen recognition by the immune system can involve different mechanisms. In particular, antigen presentation to the helper T lymphocytes requires processing of said antigens by antigen presenting cells, and their association with class II molecules of the MHC complex. This recognition essentially leads to the stimulation of specific clones of B lymphocytes, which then produce antibodies specific for the antigen.

Antigen presentation to cytotoxic T lymphocytes (CTLs), on the other hand, requires the phagocytosis of the antigen by professional cells (essentially the dendritic cells), which cells contain the appropriate MHC class I molecules and are capable of stimulating antigen-specific CTLs. This phenomenon, called "cross-presentation" of antigens or "cross-priming" of CTLs occurs for instance with viral or tumor antigens, as well as with antigens contained in apoptotic bodies (resulting from viral infection, tumors, cell degeneration, or normal cell turnover, etc.) for instance.

Cross presentation of antigens is therefore a critical pathway for the elimination of antigens that are associated with pathological conditions. The capacity to induce or facilitate the cross-priming of antigens in vivo or in vitro would represent a very powerful approach to the treatment of such pathological conditions.

As indicated above, cross-priming of antigens essentially requires the phagocytosis, by dendritic cells, of particulate antigens, i.e., antigens included in bodies comprising for instance lipids, such as phosphatidyl serine. Such particulate antigens include for instance apoptotic bodies, vesicles or cell membranes. The invention now discloses the identification of a compound involved in the phagocytosis of particulate antigens by dendritic cells. More particularly, the invention discloses the identification of a compound that mediates the interaction between particulate antigens and dendritic cells, and functions as an adaptor of cross-priming.

The invention also describes novel compositions comprising a molecule associated with the above-identified adaptor or a variant thereof.

The invention can be used to regulate the immune response, in particular to reduce the immune response or, on the contrary, to facilitate (enhance) an immune response against a desired antigen. The invention also relates to novel vectors (such as proteins or liposomes) that can be used to deliver a selected molecule to a dendritic cell. The invention also relates to methods of screening of compounds that can regulate the cross-priming of antigens or the delivery of antigens to dendritic cells, as well as to methods of monitoring the immune response in a subject.

Antigen presenting cells (APCs) contain compartments of the endocytic pathway, including multivesicular bodies (MVBs), which are sites of loading of antigenic peptides on Major Histocompatibility Complex (MHC) class II molecule. These complexes are recognized by the T lymphocytes. In particular, EBV-transformed B-lymphocytes (B-EBV) have been shown to secrete such vesicles called exosomes (Raposo et al., Mol. Biol. Cell 8 (1997) 2619). B-EBV-derived exosomes contain peptide-MHC class II complexes, and are able to present them directly to CD4+ T lymphocytes (Raposo et al., 1997). More recently, vesicles secreted by another antigen presenting cells, dendritic cells (Dcs), have been described (Zitvogel et al., Nature Medicine 4 (1998) 594). DCs are the only APCs able to induce primary and secondary immune responses. To do so, they have developed a remarkable array of specific attributes, which makes them a unique APC. DCs exist under two maturation states: immature DCs are efficient for antigen endocytosis and

phagocytosis, but inefficient for T cell activation, whereas mature DCs down regulate their internalization capacities, but express high levels of MHC and co-stimulation molecules, which makes them extremely efficient for T cell activation.

5 DCs-derived exosomes accumulate MHC class II and also bear MHC class I molecules. Exosomes produced by DCs exposed to tumor-derived antigenic peptides induce potent immune responses, leading to the rejection of established tumors (Zitvogel et al., 1998). Although the mechanisms of this spectacular anti-tumor effects are still unknown, the potency of exosome-mediated immune stimulation suggests that these vesicles may indeed  
10 mediate activation of T cell responses physiologically.

In an attempt to understand the molecular bases of the effects of DCs-derived exosomes on the immune system, the Applicants have determined the conditions of their production by DCs, and analyzed their protein composition.

15 The results obtained show that exosomes secretion is down modulated upon DC maturation, and that exosomes concentrate a limited number of proteins. In particular, besides MHC class II molecules, one major adhesion and targeting membrane protein has been identified, which behaves as the molecular effector of the effects of exosomes on the immune system, and functions to  
20 address exosomes to a cellular target, in vivo.

More particularly, the invention now demonstrates that lactadherin (also known as MFG-E8) is produced by dendritic cells, exposed at the surface of exosomes, and is involved in the phagocytosis of particulate antigens by dendritic cells. The invention also discloses variants of lactadherin, that  
25 behave as competitors of lactadherin and can be used to inhibit the phagocytosis of particulate antigens by dendritic cells. The invention also provides novel methods of delivering of molecules to dendritic cells, using vectors derived from lactadherin or variants thereof.

Mature human lactadherin is a 364 amino acid protein. Furthermore,  
30 lactadherin is a secreted protein and comprises a secretion signal. SEQ ID NO:1 represents the amino acid sequence of human lactadherin. Residues 1 to 23 (underlined) represent the secretion signal, and residues 24-387 represent the primary structure of the mature, secreted protein. The

murine, bovine and porcine lactadherin have also been identified, isolated and sequenced (see for instance Stubbs et al., PNAS 87 (1990) 8417 ; Hvarregaard et al., Eur. J. Biochem. 240 (1996) 628). The sequence of the murine lactadherin is also represented on SEQID NO:3. Amino acid residues 1-22 represent the secretion signal, and residues 23-463 represent the primary structure of the mature, secreted protein. Residues 111-147 are deleted in splicing variants of murine lactadherin.

Lactadherin has been originally described at the surface of milk fat globules (see Stubbs et al., supra). Also, this protein has been found so far essentially in mammary tissue and in cultured mammary epithelial cells. Except for their presence during lactogenesis, no function had been reported in the literature for lactadherins.

The invention now provides evidence that lactadherin is selectively produced by dendritic cells, more particularly immature dendritic cells, exposed at the surface of antigen vesicles and functions as an adaptor in antigens cross-presentation to CTLs. The invention therefore provides compositions and methods of use of lactadherin or variants thereof in the mediation of an immune response. The invention also discloses variants of lactadherin, which can be used to inhibit the cross priming, or to deliver antigens to antigen presenting cells, in particular to dendritic cells. The invention also discloses compositions comprising lactadherin or variants thereof in association with selected molecules, in particular hybrid molecules and/or liposome compositions comprising recombinant lactadherin molecules.

More particularly, it is an object of the present invention to use lactadherin or a variant thereof for the regulation of an immune response in vitro, ex vivo or in vivo. It is a particular object of this invention to use lactadherin or a variant thereof for the preparation of a composition for regulating an immune response, in particular a CTL response. It is another particular object of this invention to use lactadherin or a variant thereof for the inhibition of the cross-priming of antigens, in particular of the phagocytosis of antigens by dendritic cells.

Lactadherin comprises several functional domains. In particular lactadherin comprises two EGF-like domains, with a RGD sequence, which is

involved in integrin binding. Integrin (and more specifically integrin ( $\alpha v \beta 5$ ) being present at the surface of dendritic cells, this region of lactadherin is involved in the interaction of this protein with dendritic cells. This interaction furthermore appears to be selective. Lactadherin also comprises a domain  
5 homologous with the C-terminal region of human coagulation factors VIII and V, which represents a binding site for phospholipids, and in particular, phosphatidyl serine.

The invention now postulates and discloses that lactadherin interacts with particulate antigens, through the phospholipid binding sites, and with  
10 dendritic cells, through the RGD domain, and therefore mediates the phagocytosis of said particular antigens.

It is an object of the present invention to use lactadherin, or variants thereof, more particularly human lactadherin or variants thereof, to produce cytotoxic T lymphocytes specific for a selected antigen.

15 It is another object of the present invention to use lactadherin or variants thereof, more particularly human lactadherin or variants thereof, to deliver an antigen to dendritic cells.

Within the context of the present invention, lactadherin means a protein of mammalian origin, expressed at the surface of milk fat globules, and  
20 comprising a RGD site and a domain homologous to the factor VIII C-terminal region (i.e., a factor VIII-like domain). More specifically, the protein is of human, bovine, murine or porcine origin, more preferably of human origin. In a particular embodiment, lactadherin means human lactadherin having the sequence of SEQ ID NO: 1 or any functional analogs thereof. The term  
25 functional analogs designates natural analogs, resulting for instance from the polymorphism or from post-translational modifications, in particular from splicing(s) or single amino acid deletion, substitution or addition, with reference to SEQ ID NO: 1, and which retain at least one functional property of human lactadherin. Functional analogs also include lactadherin of other species, in  
30 particular murine lactadherin of SEQ ID NO:3.

Lactadherin used in the present invention can be either isolated from natural sources, or produced by recombinant DNA technology, as will be described below, for instance.



A "variant" of lactadherin, within the context of the present invention, means an artificial protein, i.e., a protein artificially created, and not found as such nature. Such a variant generally retains at least one biological property of lactadherin, for instance a binding property of lactadherin, and usually  
5 comprises one or several of the following alterations of the primary structure:

(a) a deletion of one or several amino acid residues, more preferably several contiguous amino acid residues. In a preferred embodiment, a deletion variant comprises a deletion of several amino acid residues, which overlap at least in part with a domain of lactadherin involved in the binding of  
10 phospholipids (PL), in particular phosphatidyl serine (PS), and/or integrin. The deletion can comprise up to 250 amino acids, preferably up to 200 amino acids, for instance. Furthermore, several deletions can be performed in one variant;

(b) a mutation in one or several amino acid residues, more preferably  
15 in at least one amino acid residue involved in the PS or integrin binding site of lactadherin. The mutation(s) can be conservative or non-conservative. Preferably, the mutation(s) in the binding site render(s) said binding site non-functional. More preferably, a variant of the invention comprises between 0 to 10 point mutations, even more preferably, 0 to 5;

(c) an addition of one or several amino acid residues. The added  
20 residues are preferably located on the N- or C- terminal end of the variant, although internal residues may also be added. The added residues can have different functions. For instance, they can represent tags that can be used in a purification method (GST, myc, etc.). The added residues can also be  
25 adaptors, that can be used for the association of the variant to a selected molecule such as an antigen, a nucleic acid, a receptor or a membrane lipid. Such adaptors can be for instance polylysine, other basic amino acids, a spacer, or any other DNA binding motif. The adaptor can also be a trafficking signal, such as a transmembrane domain of a protein or a lipid, for instance.  
30 Furthermore, the added residues can also represent a selected molecule, fused to the lactadherin, as will be discussed in more details below.

Also, as indicated above, variants according to this invention can combine one or several modifications of one or several of the above types.

A particular variant of lactadherin of this invention is a variant lacking a functional PL binding site (in particular a functional PS binding site) and/or a functional integrin binding site.

5 Variants lacking a functional PL binding site are essentially incapable of efficiently binding phospholipids such as phosphatidyl serine. Such variants however, may retain a functional integrin binding site and thus behave as competitors of natural lactadherin. Variants lacking a functional PL (i.e., phosphatidyl serine) binding site can be obtained by different methods. In a particular embodiment, said variants lack all or part of the phosphatidyl serine  
10 (PS) binding site. In another particular embodiment, such variants comprise a mutated PS binding site. Of course, variants of this invention can also comprise both deletion and mutation in the PS binding site. The phosphatidyl serine binding site of lactadherin essentially lies in the C-terminal amino acid residues of lactadherin, more particularly in the 150 C-terminal amino acid  
15 residues. A variant according to this invention is therefore any variant of lactadherin having a mutation and/or a deletion in/of the 150 C-terminal amino acid residues, and essentially incapable of binding phosphatidyl serine. A more preferred variant is a polypeptide comprising the sequence of SEQ ID NO:1, said sequence further comprising a mutation and/or a deletion  
20 in any one of amino acid residues 242 to 387.

In a particular embodiment of this invention, the variant comprises a deletion of at least 5, preferably at least 10, even more preferably at least 20 contiguous amino acids of the above C-terminal region. In a particular  
25 embodiment, the deletion encompasses the entire 150 C-terminal amino acid residues, more preferably the amino acid residues 242 to 387 of SEQ ID NO:1. Another specific embodiment of this invention is a lactadherin lacking the 25 C-terminal amino acids, in particular a polypeptide comprising amino acid residues 24-363 of SEQ ID NO: 1 or a polypeptide comprising amino acid residues 23-439 of SEQ ID NO:3.

30 Examples of mutations include any suppression or substitution of one or several single amino acid residues in the 150 C-terminal region of lactadherin. The substitution can be either conservative or non-conservative, preferably nonconservative.

Particular examples of mutated variants of this invention include any lactadherin having one or several point mutation(s) in the 25 C-terminal amino acids, and essentially incapable of binding PS. More particular examples are polypeptides of SEQ ID NO:2 or 4, having one or several point mutation(s) in the 25 C-terminal amino acids.

These variants of the present invention are particularly interesting since they are capable of binding integrin  $\alpha v \beta 5$ , i.e., dendritic cells, more preferably immature (human) dendritic cells, while they are essentially incapable of binding PS. These variants are particularly suited for the delivery of molecules to dendritic cells, in particular for the delivery of antigenic molecules to dendritic cells. These variants can also facilitate the cross-presentation of a selected antigen by dendritic cells, and thus the development of a specific CTL response against a selected antigenic molecule.

Variants of lactadherin lacking a functional integrin binding site are essentially incapable of binding efficiently dendritic cells. Such polypeptides can be any variant of lactadherin lacking all or part of the integrin binding site or which comprise a mutated integrin binding site. The integrin binding site of lactadherin essentially resides in an RGD motif located in the N-terminal part of the molecule. For instance, the integrin binding site of human lactadherin of SEQ ID NO:1 lies in residues 46-48 and the integrin binding site of murine lactadherin of SEQ ID NO:4 lies in residues 87-89. The invention therefore resides, in any lactadherin comprising a mutation in and/or a deletion in or of the RGD motif, and which is essentially incapable of binding dendritic cells. Particular examples of such variants are polypeptides of SEQ ID NO:1 which lack one, two or all of the amino acid residues RGD at position 46-48, and polypeptides of SEQ ID NO:4 which lack one, two or all of the amino acid residues RGD at position 87-89.

Such variants can be used for instance to interfere with the cross-priming of antigens, in vitro, ex vivo or in vivo, by competing with naturally occurring lactadherin for the binding to particulate antigens. Other types of inhibitors are represented by polypeptides comprising essentially the phospholipid binding site of lactadherin, for instance peptides comprising essentially the amino acid residues 364-385 of SEQ ID NO:1, or variants

thereof. Other inhibitors are represented by antibodies specific for lactadherin, in particular for lactadherin PL or integrin binding sites. Such antibodies (either polyclonals or monoclonals) can be raised by immunisation of an animal using corresponding peptides, and used to reduce an immune reaction.

5           Accordingly, an object of the present invention resides also in a variant of lactadherin which lacks a functional PL or integrin binding site.

          The above variants can be prepared according to conventional techniques, known to the skilled artisan, and disclosed in more details in the Examples. For instance, they can be produced by recombinant DNA  
10           techniques, starting from a nucleic acid molecule encoding lactadherin. More particularly, a nucleic acid construct encoding lactadherin as defined above can be provided and modified according to conventional techniques to introduce mutation(s) and/or deletion(s) therein. Such techniques include digestion with restriction enzymes and/or exonucleases, ligation, site-directed  
15           mutagenesis, amplification, artificial nucleotide synthesis and the like. Such modifications can be performed in vitro, on isolated nucleic acid, generally produced or replicated in a competent host cell, such as eukaryotic or prokaryotic cells, or obtained by amplification with specific primers from a dendritic cell, for instance. In this regard, the invention also relates to a nucleic  
20           acid encoding a polypeptide as defined above. Said nucleic acid can be a DNA or a RNA molecule, or a synthetic nucleic acid. The invention also relates to any vector comprising a nucleic acid as defined above. Such vectors can be plasmids, cosmids, episomes, YACS, viral vectors, etc. Preferred vectors also comprise a promoter region that causes expression of the nucleic  
25           acid, as well as, optionally, a transcription termination signal (i.e., a polyadenylation sequence). The construction of such vectors and the choice of the promoter region can be made by the skilled artisan according to conventional techniques and routine experimentation. In particular, the vector can be a plasmid derived from pUC, pIC, pBR or pBS, or a viral vector  
30           prepared from retroviruses, adenoviruses or AAV, for instance. The invention also relates to a cell comprising a nucleic acid or a vector as defined above, and to their use, for instance in the production of variants -as described above. The recombinant cell of the present invention can be prokaryotic (such as a

bacteria) or eukaryotic, such as a yeast cell, a mammalian cell, an insect cell, etc. Said cells can be prepared by conventional techniques (electroporation, precipitation, gene gun, lipid-mediated transfection, etc.).

5 Another object of this invention lies in a composition comprising a variant of lactadherin which lacks a functional PL or integrin binding site. Such a composition can be used for instance to modulate the cross-priming of antigens.

A particular object of this invention lies in a composition comprising lactadherin or a variant thereof in association with a selected molecule.

10 Indeed, the invention also lies in the use of lactadherin or variants to deliver molecules to dendritic cells.

In this respect, any selected molecule can be associated to lactadherin or a variant thereof as disclosed above, in order to deliver said molecule to dendritic cells in vitro, ex vivo or in vivo, and/or to induce a CTL response. The selected molecule can be associated to lactadherin or a variant thereof in different manner, covalently or non covalently. Covalent association (binding) can be obtained either by chemical, enzymatic or genetic methods. In particular, chemical coupling can be made using conventional chemical adaptors and/or reactions, in particular by amide, amine, or acid bounds, with or without spacers such as cabonyidiimidazole, etc.

20 Chemical coupling can also be obtained using the streptavidin / biotin system or any other analogous method.

One particular method of coupling the selected molecule to the lactadherin involves recombinant DNA constructs (i.e., genetic coupling). In this regard, a chimeric nucleic acid can be prepared comprising a region encoding lactadherin or the variant thereof and a region encoding the selected polypeptide, operably linked together, i.e., in the same reading frame, so that, upon expression in a host cell, a fusion (chimeric) protein is obtained. The selected polypeptide (or peptide) can be fused to lactadherin or a variant thereof in N-terminal or C-terminal position. Preferably, the selected polypeptide or peptide (i.e., the heterologous moiety) is fused at the C-terminal end of lactadherin or a variant thereof according to this invention.

Accordingly, a particular object of the present invention resides in a chimeric protein (or polypeptide) comprising lactadherin or a variant thereof fused to a heterologous polypeptide or moiety.

5 Another particular object of the present invention lies in a product comprising lactadherin or a variant thereof coupled to a heterologous molecule. As indicated above, coupling can be covalent or non covalent.

Also, since lactadherin mediates the phagocytosis of particulate antigens, the invention also discloses artificial liposomes (or lipid vesicles) comprising lactadherin (preferably recombinant) or a variant thereof as  
10 disclosed above.

Lactadherin can be bound to the surface of the liposome, through its PL binding site. In this embodiment, the artificial liposome of this invention preferably comprises at least phosphatidyl serine as a constituent lipid. Lactadherin or the variant thereof can also be bound to the liposome  
15 membrane through a receptor moiety, capable of binding a ligand moiety present in the membrane of the liposome. In particular, as indicated above, a variant of lactadherin can be prepared comprising added residues or structure, which provide for the binding of said lactadherin variant to a selected receptor or ligand. In a particular embodiment, the variant of lactadherin comprises a  
20 peptide which binds a receptor present in the liposome membrane. The peptide can be biotin, which binds to streptavidin introduced in the liposome membrane.

In another particular embodiment, lactadherin or the variant is enclosed in the membrane of the liposome. The insertion (anchoring) can be achieved  
25 in particular by using a variant of lactadherin comprising an anchoring region, such as for instance a transmembrane domain. Such an anchoring region can be introduced in the variant as added residues in addition or in replacement of residues of lactadherin, and in particular in replacement of the PL binding site. The insertion can also be achieved by using a variant of lactadherin  
30 comprising a lipid at one of its extremities, preferably its C-terminal end, according to methods known to the skilled artisan. In this specific embodiment, a lipid (e.g. a fatty acid) is bound to the C-terminal end of

lactadherin or a variant thereof having the capacity to bind integrin, using conventional method, and the resulting product is contacted with the liposome.

Thus, the invention also relates to any lipid vesicle composition comprising a recombinant protein comprising at least the integrin binding site of lactadherin, more preferably of human lactadherin. The lipid vesicle can be prepared according to known techniques. For instance, the selected lipids are contacted together in the appropriate medium to form lipid bilayers and vesicles. Lactadherin or the variant thereof can be added to the product before, during or after formation of the artificial liposomes. Also, an artificial liposome includes an exosome produced by a cell, which comprises a recombinant lactadherin molecule.

The invention also relates to a polypeptide comprising (a) a lactadherin amino acid sequence lacking a functional PL binding site and (b) a heterologous moiety allowing anchoring of said polypeptide in a lipid membrane.

The liposome compositions of this invention advantageously further comprise at least one selected molecule, such as an antigen. The selected molecule can be a lipid, polypeptide, nucleic acid, chemical molecule, etc.

Preferably, the selected molecule is a polypeptide (such as any protein, peptide, etc.) or a nucleic acid.

In this regard, the invention also relates to a polypeptide comprising (a) a lactadherin amino acid sequence lacking a functional PL binding site and (b) a heterologous moiety allowing binding of said polypeptide to a nucleic acid. Such a polypeptide is able to form complexes with nucleic acids, such as plasmids, for instance, and to target said nucleic acids to dendritic cells in vitro, ex vivo or in vivo. This invention also relates to a nucleic acid encoding the primary structure of the above polypeptide.

Even more preferably, the molecule is an antigen, i.e., a compound against which an immune response is sought, particularly a CTL response, a cytokine (such as IL12, IL4, GM-CSF, etc., which can stimulate the activation and/or differentiation of dendritic cells, for instance) or a toxic molecule, which may be used to eliminate dendritic cells.

Examples of antigen molecules comprise for instance viral proteins or peptides, bacterial proteins or peptides, or tumor antigens, such as MART-1, MAGE, BAGE, PSA, p53, Rb, Ras, etc. The antigen can be intact (the entire proteins) or in the form of a fragment thereof.

5 A preferred embodiment of the present invention is an immunogenic composition comprising lactadherin or a variant thereof in association with a selected antigenic molecule. Vaccines or immunogenic compositions of this invention can be used in any mammal, such as human beings or animals.

10 The antigenic molecule may be any protein, polypeptide or peptide, bearing one or several epitopes, a virus, a fragment of a virus, a viral protein, polypeptide or peptide, a bacteria, etc. Furthermore, the virus or bacteria may be inactivated or attenuated (i.e., with low infectivity or pathogenicity. The virus or bacteria may represent the antigen itself, or a carrier of the antigen. In a particular embodiment, the invention thus resides in an immunogenic  
15 composition comprising a virus or a bacteria, wherein said virus or bacteria expresses lactadherin or a variant thereof at its surface. Lactadherin or a variant thereof can be expressed as a result of chemical, genetic, enzymatic or non-covalent coupling.

In a particular embodiment, the invention resides in a recombinant virus,  
20 wherein said recombinant virus expresses lactadherin or a variant thereof as a surface molecule. The virus may be any retrovirus, adenovirus, AAV, herpes virus, etc. Lactadherin or the variant may for instant be expressed as a genetic fusion with an envelope protein. The recombinant virus may further comprise a recombinant genome encoding a protein, polypeptide or peptide, including an  
25 immunogen or a immuno-stimulatory molecule.

In another particular embodiment, the invention resides in a recombinant cell, wherein said recombinant cell expresses lactadherin or a variant thereof as a surface molecule. More preferably, the recombinant cell is derived from a pathogenic bacteria. These recombinant bacteriae thus  
30 represent improved immunogenic compositions which can be used to produce efficient immune reactions in vivo or in vitro, in particular efficient CTL responses. The recombinant cells may be produced by expression, in said cells, of a nucleic acid encoding lactadherin or a variant thereof, optionally



bound to a signal peptide allowing anchoring of the molecule into the cell membrane. Lactadherin or the variant may also be expressed through contacting of the cells in vitro with lactadherin or the variant.

5 In this regard, the invention also relates to a hybrid polypeptide comprising (a) a lactadherin amino acid sequence lacking a functional PL binding site fused to (b) an antigenic polypeptide or peptide. The invention also relates to any nucleic acid encoding such a hybrid polypeptide. Said polypeptides and nucleic acids can be used to prepare vaccine compositions, in particular anti-tumor vaccine compositions, which can be administered in  
10 naked form, for instance by intramuscular injection.

The selected molecule can be present in the cytosol of the liposome and/or anchored into its membrane and/or bound to the surface of said liposome. The selected molecule can be combined with the liposome according to conventional methods as disclosed above, in particular by  
15 incubation of the molecule with the constituent lipids, prior to or during formation of the liposome.

The invention also relates to a recombinant host cell, in particular a recombinant bacteria, expressing a lactadherin or variant thereof. More preferably, the recombinant bacteria expresses lactadherin or a variant thereof  
20 having the capacity to bind integrin. The introduction of recombinant lactadherin or variant in bacteria, for instance, allows the uptake of bacterial membrane fractions by dendritic cells, and the efficient generation of immune responses against bacterial antigens, for instance.

The compositions, variants, chimeric proteins or liposomes of this  
25 invention can be used in vitro, ex vivo or in vivo. In vitro, they can be used to pulse or sensitize dendritic cells to a desired molecule, for instance. In this respect, the invention also discloses a method of delivering a molecule to a dendritic cell, preferably an immature dendritic cell, in vitro, ex vivo or in vivo, comprising contacting said dendritic cell (or a population of cells comprising a  
30 dendritic cell) with a compound, composition or chimeric protein as defined above. This method can be performed in any appropriate device (plate, dish, tubes, flask, etc.) with concentration of lactadherin or a variant thereof ranging from 0,01 to 1 000 µg/ml, for instance.

The variants of lactadherin can also be used to target any compound to dendritic cells, in vitro, ex vivo or in vivo. For instance, the above disclosed variants of lactadherin having a functional integrin binding site can be used to target a vector (such as a viral, a polymeric, a cationic or a polypeptide vector) to dendritic cells. Particular examples include a recombinant adenovirus. Therefore, the invention also relates to the use of lactadherin or a variant thereof having a functional integrin binding site to target a vector (such as a viral, a polymeric, a cationin or a polypeptide vector) to dendritic cells. The invention also discloses a composition comprising a vector associated with lactadherin or a variant thereof.

The compositions, variants, chimeric proteins or liposomes of this invention can also be used in vitro in a method of screening and/or identifying compounds that can regulate the cross-priming of antigens and/or the phagocytosis of antigens and/or the delivery of molecules to dendritic cells. In particular, dendritic cells can be contacted with compositions, variants, chimeric proteins or liposomes of the present invention, in the presence of a candidate product or mixture, and the capacity of said candidate product or mixture to inhibit or facilitate the uptake (or binding) of said compositions can be measured.

The invention also relates to a method of screening (essentially in vitro) of compounds having the ability to induce or inhibit the expression of lactadherin. In this respect, the invention provides a method comprising (i) contacting a test compound (or mixture) with a cell culture producing a reference level of lactadherin, (ii) measuring the quantity of lactadherin produced by said cell culture, and (iii) comparing said quantity with the reference level. The cell culture can be for instance dendritic cells, preferably an established dendritic cell line. The dosage of lactadherin can be made according to conventional techniques, such as immunoassay with specific antibodies, PCR, etc. Compounds capable of increasing the expression on lactadherin may be used to stimulate the immunity of a subject, in particular the CTL response of a subject.

The invention also relates to labeled compositions or variants as described above, and their use in the monitoring of an immune response. In

particular, the invention can be used to detect the presence of exosomes in a biological sample, and to correlate the level of exosomes to a physiological state of a subject. A detection method comprises -for instance the collection of a sample (such as a blood sample of a subject), the contacting of said sample  
5 with a composition comprising lactadherin or a variant thereof having the ability to bind integrin, and the detection of the presence (and optionally the quantity) of exosomes bound to said lactadherin or variant thereof. The diagnostic of high levels of exosomes in a biological sample can be correlated with a pathological condition where exosomes are produced, for instance by dendritic  
10 cells (such as tumor, viral infection, etc.).

In vivo, the invention can be used to modulate an immune response, deliver a molecule to dendritic cells, modulate the phagocytosis of antigens and/or for cross-priming of antigens, and also for the monitoring of an immune response. In particular, the invention also relates to the use of lactadherin,  
15 preferably human lactadherin, or a nucleic acid encoding the same, for the stimulation of an immune response in a subject. In particular, the delivery of human lactadherin or a nucleic acid encoding the same in a subject affected with a tumor would enhance the immune response of said subject against the tumor. For this specific application, intratumoral administration would be  
20 preferred.

For in vivo applications, conventional dosages can be used and adapted by the skilled artisan. Preferably, for use in vivo, the compositions are administered by injection, such as i.v., i.a., i.p., s.c., i.m., for instance. They also can be administered by any other route. Preferably, they are formulated  
25 with appropriate acceptable vehicles, such as buffers (phosphate, potassium, chloride, etc.), isotonic solutions, saline solutions, at appropriate dosage, such as for instance between 0,1 and 10000 µg of protein by single dosage unit. The compositions may also comprise stabilizing agents (such as gets, high molecular weigh molecules, i.e., albumin, dextran, etc.), surfactants, etc.

30 Other aspects and advantages of the present invention will be disclosed in the following examples, which should be considered as illustrative and non limiting.

### Legend to the Figures

Figure 1: Overall protein composition of metabolically-labeled exosomes and D1 cells.

Exosomes purified from the supernatant of metabolically-labeled D1 cells were run on a 12% SDS gel (Exos), together with lysate (including both cytosolic and membrane components) obtained from the whole cells (Cells), or cytosol (cyto) or total membranes (mb) prepared from the same cells in the absence of detergent. The dried gel was autoradiographed for 24h (proteins bigger than 45 kDa) or 48 h (proteins smaller than 45kDa). A pic profile of each lane was obtained with the NIHimage software. Stars point to proteins abundant in the cells and absent in exosomes, dots to proteins enriched in exosomes.

Figure 2: Protein profile of D1 exosomes as seen by coomassie blue staining.

Thirty µg of exosomes were separated on a 8-15% gradient SDS gel, and stained with coomassie brilliant blue. The band pattern is identical to that obtained with metabolically-labeled exosomes. The major bands (1 to 11) were analyzed by trypsin digestion and MALDI-TOF (see table 1)

Figure 3: Western blot analysis of lactadherm expression in mouse DC-derived exosomes. Abundant immune reactivity was found with serum A on DC-derived exosomes, but not on whole cell lysates. Intermediate reactivity was detected on tumor cell-derived exosomes (TS/A, a mammary cell carcinoma) or in isolated membrane preparations from DCs. Annexin specific antibodies reacted with all exosome preparations and cell lysates.

Figure 4: FACscan analysis of lactadherin expression on D1 -derived exosomes. Exosome- or FCS-coated latex beads were incubated with anti-lactadherin antibodies (serum A) or the corresponding pre-immune serum. The beads were then incubated with secondary FITC labeled anti-rabbit antibodies before FACscan analysis. Abundant specific staining of exosomes coated beads was found with serum A, but not with the pre-immune serum.

Figure 5: FACscan analysis of lactadherin expression on D1 -derived exosomes. Exosome- or FCS-coated latex beads were incubated with anti-MHC class I, antiMHC class II, control IgG2a antibodies or anti-lactadherin monoclonal (MC3 or MC8) or polyclonal antibodies (serum B). Antibody binding to the beads was revealed with FITC-labeled anti-mouse or anti-rabbit IgG antibodies (Jackson Laboratories), before FACscan analysis. Strong staining of the exosome coated beads was found with the anti-MHC class I and II, as well as with the different antilactadherin monoclonal and polyclonal antibodies.

### Materials and Methods

#### Cell lines

The spleen-derived murine DC cell line D1 has been described previously (Winzier et al., 1997). It was cultured in Iscove's Modified Dulbecco's Medium (IMDM, Sigma, St Quentin, France) supplemented with 10% endotoxin-free fetal calf serum (FCS, Life Technologies, Cergy, France) and 30% R1 medium (GMCSF-transfected NIH-3T3 fibroblasts conditioned medium). Cells were passaged twice a week in 145 mm non tissue-culture treated Petri dishes (4-5.10<sup>6</sup> cells per dish). To control their non-activated state, the level of cell surface expression of MHC class II and costimulatory molecules was checked regularly by fluorescence-activated cell scanning (FACS) as described (Winzier et al., 1997).

#### Immun-electron microscopy

D1 cells, either immature or mature after treatment for 24 hours with LPS were fixed with 2% paraformaldehyde in phosphate buffer 0.2M pH 7.4 (PB) for 2 hours at room temperature. Fixed cells were processed for ultrathin sectioning and immunolabeling as described previously (Raposo et al. 1997; Liou et al., 1996). Briefly, after washing with PB and PB-50 mM glycine, cells were embedded in 7.5 % gelatine. Small blocks were infiltrated with 2.3M sucrose at 4 °C for 2 hours and then frozen in liquid nitrogen. Ultrathin

cryosections prepared with a Leica ultracut-FCS (Wien, Austria) were retrieved with a mixture of Methycellulose and 2.3 M sucrose (vol./vol.) and indirectly immunogold labeled with the rat monoclonal anti-class II antibody M5114, followed by polyclonal anti-rat polyclonal antibodies (Dako, Danemark) and Protein A gold (purchased from Dr. J.W. Slot, Department of Cell Biology, Utrecht University, The Netherlands).

The sections were finally contrasted and embedded in a mixture of methylcellulose and uranyl acetate and viewed under a CM120 Twin Phillips electron microscope (Eindhoven, The Netherlands).

#### Exosomes purification

Exosomes were prepared either from the supernatant of a 3 days-old D1 culture, or from fresh culture medium incubated for 24h with 3 days-old D1 cells. We could not evidence any difference in the overall composition of exosomes purified from 3 days- or from 24h-supernatants. Exosomes were purified as previously described (Raposo et al., 1996). Briefly, the medium was cleared from cells and debris by 3 successive centrifugations at 300g (5 min), 1,200g (20 min) and 1 0,000g (30 min), then exosomes were recovered in the pellet after centrifugation for 1 h at 70,000g. Exosomes were washed once in a large volume of PBS, centrifuged at 70,000g for 1 h and resuspended in 50-200 ml of PBS with 0,01% sodium azide (NaN<sub>3</sub>). The amount of exosomal proteins recovered was measured by Bradford assay (Biorad, Ivry, France).

#### Exosomes floatation on sucrose gradient

Ninety mg of exosomes were resuspended in 1 ml Hepes 20mM, pH 7.2 containing 2.5M sucrose and a cocktail of protease inhibitors (see next section). A continuous 2M - 0.25M sucrose gradient was loaded on top of exosomes, and this was centrifuged for 16h at 35,000 rpm in an SW41 rotor. Fractions (1 ml each) were collected from the top of the gradient, centrifuged for 1 h at 1 00,000g, and the pellet was loaded on a 10% SDS gel for western blot analysis.

### Protein analysis by SDS-PAGE

Total proteins were prepared from 108 D1 cells lysed in 1 ml of Tris 50mM pH 7.5, NaCl 0.3M, ThonX-100 0.5%, NaN<sub>3</sub> 0.1%, with a cocktail of antiproteases (CLAP: chymostatine, leupeptine, aprotinin, pepstatin, 100mM each, Sigma) for 5 min at 4°C. Lysates were cleared from nuclei by centrifugation at 10,000g. To separate cytosol and total membranes, approximately 2.107 D1 cells were resuspended at 4°C in 0.3 ml of Triethanolamine 10 mM, EDTA 1 mM, acetic acid 10 mM, sucrose 250mM titrated to pH7.4 (TEA-sucrose) supplemented with CLAP, and homogenized by 60 Passages through a 25G needle. Nuclei and cell debris were cleared by centrifugation for 10 min at 1,200g. The postnuclear supernatant was centrifuged for 1 h at 100,000g: cytosol was then recovered in the supernatant, and the pellet (total membranes) was resuspended in 0.3 ml of TEA-sucrose-CLAP.

### Metabolic labeling of cells and exosomes

Metabolic labeling of D1 cells was performed on 3-days-old cultures: cells were washed once in Methionine/Cysteine-free RPMI, starved for 1h at 37°C in Methionine/Cysteine-free RPMI supplemented with 30% dialysed R1 medium, and incubated overnight at 37°C in 20ml fresh Methionine/Cysteine-free RPMI-dialysed R1 supplemented with 5% endotoxin-free FCS and 10-20mCi/ml 35S-Methionine/Cysteine (Promix 35S, ICN, Orsay, France). Labeling medium was removed, cells were washed once in complete D1 culture medium, and further incubated for 24h in complete medium at 37°C. Exosomes were purified from the supernatant; total lysates, cytosol and total membranes were prepared from the cells. Proteins (20,000cpm of each sample) were separated on a 12% SDS-PAGE, dried and autoradiographed. The profile of each lane was obtained using the N1Himage software.

### Protein analysis by MALDI-TOF

Thirty mg of proteins from exosomes or total lysates were run on a 6-15% SDS-PAGE, and stained with Coomassie blue (Biorad). The major bands

in the exosomes preparation were excised from the gel. Briefly, proteins were digested with trypsin for 4h at 37°C, and the peptide profile generated was analyzed by Matrix-Assisted Laser Desorption/Ionisation - Time of Flight (MALDI-TOF, ). The peptide profile of each band was compared to those of proteins in the databases using the MS-Fit program.

#### Western blot

Exosome preparations were resolved by SDS-PAGE and the proteins were transferred to PVDF membranes. Antibody reactivity was detected using specific secondary HRP-labeled anti-rabbit IgG antibodies (Jackson Laboratories) and ECL (Amersham).

#### FACscan analysis of exosomes

A new assay based on the chemical cross linking of exosomes to activated latex beads (Surfactant-free white aldehyde/sulfate latex, D : 3,9 µm, Interfacial Dynamics Corp., Portland, Or. USA) was used to detect lactadherin on DC-derived exosomes. Coating was performed by incubating 10 µl of beads with 30µg of purified exosomes for 2 h at room temperature. The exosome-coated beads were saturated in 1M glycine for 30 min at RT and incubated with the specific and FITC-secondary antibodies (anti-mouse or anti-rabbit IgG, Jackson Laboratories) in PBS 3% FCS, before analysis with a Facscalibur (Becton Dickinson).

#### Human DC culture

Blood cells from healthy volunteers were obtained by apheresis (Cobe Spectra cell separator). Mononuclear cells were isolated by Ficoll-Paque (Pharmacia) density gradient. Plastic adherent PBMC (peripheral blood mononuclear cells) from healthy donor were incubated for 7 days with GM-CSF and IL-4 or IL-13, in RPIM-1640 (Life Technologies) medium supplemented with 10% fetal calf serum. At the end of the culture the cells were analyzed by flow cytometry for their phenotype for CD1a, CD3, CD14, CD19, CD15, CD40, CD80, CD83, CD86, and anti HLA-DR. They exhibited phenotype characteristic of immature dendritic cells as previously described in Chapuis et al., Eur. J. Immunol, 1997, 27:431-441 (i.e. for CD1a+, CD3 -,



CD14-, CD19 -, CD15 -, CD40 +, CD80 +, CD83 -, CD86 +, and anti HLA-DR+). The exosomes were harvested from the culture supernatant as performed for exosomes from the D1 cell line.

## 5            Examples

### 1.        Overall protein composition of exosomes

10            In order to understand the molecular basis of exosome's anti-tumoral effect in vivo, we undertook an extensive characterization of the protein composition of exosomes. D1 cells were metabolically labeled overnight with 35S-Methionine/Cysteine mix, washed once, and fresh non-radioactive medium was added to the cells for 24h. Metabolically labeled exosomes were purified from this supernatant. Out of 2 independent experiments, the amount of radioactivity recovered in exosomes was 0.25% ( $\pm 0.05\%$ ) of the radioactivity incorporated into the cells. The amount of radioactivity recovered in exosomal proteins (80 cpm/mg) was similar to that recovered in proteins from the whole cells (100 cpm/mg), confirming that exosomal preparations are composed of cell-derived proteins, and are not contaminated by proteins from the extracellular medium.

20            The protein profile of exosomes from metabolically labeled cells was analyzed by SDS-PAGE and autoradiography and compared to that of whole D1 lysates, of cytosol or of total cellular membranes. As shown in figure 1, exosomes displayed a unique protein composition pattern. At least 7 proteins (of approximately 180, 90, 70, 58, 43, 32 and 27 kDa see dots in figure 1, 'exos' panel) were strongly enriched in exosome preparations as compared to whole cells, cytosol or total membranes. Eight other major proteins from whole cells, cytosol or total membranes were absent or less abundant in exosomes (see stars in figure 1, 'cells' panel). Interestingly, two of the bands enriched in exosomes (70 and 58 kDa) are not detected in the cytosol or the whole D 1 cells, suggesting a particularly strong mechanism of enrichment of this protein in the exosomes.

Therefore, exosomes concentrate a unique subset of cellular proteins, which most likely account for exosome's biological activities. To identify the proteins present in exosomes, thirty micrograms of exosomal proteins were loaded on a 8-15% SDS gel : the pattern of bands stained by Coomassie brilliant blue was very similar to that of metabolically labeled exosomes (compare figures 1 and 2). Therefore, all the major protein species in the exosome preparations are from cellular, and not fetal calf serum (FCS), origin. All these major bands (bands 1 to 11 in figure 2) were excised, trypsin-digested and the peptides s generated were analyzed by Matrix-Assisted Laser Desorption Ionisation - Time of Flight (MALDI-TOF). The peptide profiles generated for the different bands were compared to the theoretical tryptic-peptide profiles of known proteins from the data bases. The results obtained (see Table 1 below) show that, among the identified bands, one is lactadherin (also known as Milk Fat Globule-EGFio FactorVill, MFG-E8), a peripheral membrane-associated protein.

Table 1

Band	Protein	Matching Peptide	Total Number of Peptides
4	Lactadherin	10	28
	+ hsc73	11	
5	Lactadherin	12	15

## 20 2. Dendritic cells but not macrophages produce Lactadherin

In view of the above evidence of the, presence of lactadherin on exosomes produced by dendritic cells, dendritic cells have been analyzed to determine if they were producing lactadherin. For that purpose, an amplification reaction has been performed on total RNA prepared from dendritic cells using oligonucleotide primers specific for the MRNA of lactadherin. The sequence of the oligonucleotides is the following:

Oligo 1 (SEQ ID NO:5): 5'-ATGCTACTCTGCGCCTCTG-3'

Oligo 2 (SEQ ID NO:6): 5'-GTCTTGTAGCTGCTGGAGG-3'

5        Total RNA was prepared from  $5-7 \times 10^6$  cells by the guanidine thiocyanate method (Chomezinski and Sacchi, *Annal. Biochem.* 162 (1987) 156). Reverse transcription was performed in a 20  $\mu$ l volume: 1  $\mu$ g of RNA was mixed with dNTPs (250  $\mu$ M each final), random hexanucleotides (2 ng, Gibco-BRL), and RNAsin (20 U, Promega) in a final volume of 15  $\mu$ l, heated at 60°C for 5 minutes, and cooled down to 42°C. Four  $\mu$ l of 5x AMV-Reverse Transcriptase (RT) buffer and 1  $\mu$ l of AMV-RT (25 U/ $\mu$ l, Boehringer) were added, and the reaction was performed at 42°C for 2 h. The PCR reaction was performed in a final volume of 50  $\mu$ l, using 3.5  $\mu$ l of the reverse transcription reaction, dNTPs (200  $\mu$ M each final),  $MgCl_2$  (2 mM final), Taq or Tfi polymerase (Promega) and ofigonucleotides specific for the mouse MFG-E8 CDNA (500 nM each final). The mixture was heated at 94°C for 5 minutes, submitted to 35 cycles of (94°C 30 Secondes, 53°C 30 secondes, 72°C 45 secondes), and finally to 72°C for 2 minutes. As a control, a similar PCR reaction was set up with oligonucleotides specific for the mouse actin cDNA, and submitted to 25 cycles of (94°C 30 secondes, 55°C 30 secondes and 72°C 30 secondes). Twenty  $\mu$ l of the PCR reactions were run on a 1 % agarose gel containing ethidium bromide, and observed under UV illumination. The band amplified were of 830 bp for MFG-E8, and 800 bp for actin.

25        Expression of the gene coding for MFG-E8 was analyzed by RT-PCR in different murine cell lines: D1 (dendritic cell line), J774 (macrophage cell fine), P815 (mastocytoma), and TS/A (mammary adenocarcinoma). D1 were used either in their immature state, or after 24 h treatment in the presence of LPS, that induces their maturation. Expression of MFG-E8 was detected only in immature D1 cells and in the TS/A mammary carcinoma: neither mature D1 cells, nor macrophages or mastocytoma expressed MFG-E8. The good quality of the cDNAs was shown by the amplification of an actin band from all the samples.

### 3. Lactadherin expression in mouse and human DCs and DC-derived exosomes - Production of antibodies

In this example, antibodies directed against human or mouse lactadherin have been prepared. These antibodies have been used to monitor the presence and expression of lactadherin in mouse and human DC and DC-derived exosomes. These antibodies can also be used to inhibit the interaction between particulate antigens and DCs.

Three different rabbit anti-sera were raised against human and mouse lactadherin peptides. The peptides, synthesized artificially, comprise the RGD domain of lactadherin, and have the following sequence:

- CLVTLDTQRGDIFTEY (residues 79 to 94 of SEQ ID NO: 4) for the RGD domain of mouse lactadherin. This peptide was used to produce serum A.

- CEEISQEVVRGDIVFPSY (residues 38 to 53 of SEQ ID NO: 1) for the RGD domain of human lactadherin. This peptide was used to produce serum B.

- a mixture of three peptides homologous in mouse and human lactadherin CEYLKTFKVAYSLLDG (residues 153 to 166 of SEQ ID NO: 1), CVTGIIITQGARDFG (residues 299 to 311 of SEQ ID NO: 1) and 20 LPVS TLRL (residues 370 to 387 of SEQ ID NO: 1). These peptides were used to produce serum C.

The rabbits reacted to all peptides, except the last one.

Serum A reacted very strongly with a unique band of 50-55 kDa when exosomes from immature D1 cells or from fresh bone marrow-derived DCs were analyzed by western blot (figure 3, left panels). Reactivity was barely detectable on whole D1 cell lysates, but could be evidenced when isolated membranes were used (figure 3, right panel). Equal protein amounts, 2 or 6 µg/lane, were deposited and the quality of the deposits was evaluated using an anti-annexin II antibodies in parallel (figure 3, lower panel).

A FACscan analysis assay based on the chemical cross linking of exosomes to activated latex beads was used to detect lactadherin on DC-

derived exosomes. Antimouse lactadherin antibodies (serum A), but not the corresponding pre-immune serum, also reacted with exosome-coated latex beads (figure 4).

Antibodies directed to MHC class I (HC10) and H (IB5) molecules  
5 reacted with human DC-derived exosome-coated beads, but not with control FCS-coated ones (figure 4). Likewise, two anti-human lactadherin monoclonal antibodies MC3 and MC8 also bind exosome- but not FCS- coated beads. Similar results were obtained using polyclonal antibodies to lactadherin (serum B), which, in contrast to the corresponding pre-immune serum, also bind to  
10 exosomes (figure 5).

These results clearly show that both murine and human DC-derived exosomes bear lactadherin. The peptides and antibodies disclosed in this example can be used in other methods of this invention.

15

4. Construction of a variant of human lactadherin lacking a functional integrin binding site.

This example discloses a method for the construction of variants of  
20 lactadherin lacking a functional integrin binding site. The variants obtained are essentially incapable of binding to integrin, more specifically to integrin  $\alpha v \beta 5$ . Said variants therefore do not efficiently bind dendritic cells, more particularly human dendritic cells, especially human immature dendritic cells. More preferably, these variants retain the ability to bind phospholipids, in particular  
25 phosphatidyl serine. These molecules indeed represent competitors of naturally occurring lactadherin for the binding of particulate antigens, such as apoptotic bodies or vesicles, and interfere with the development of an immune response, especially with the cross-priming of antigens.

The variants of lactadherin lacking a functional integrin binding site are  
30 constructed according to the following method.

A nucleic acid construct is provided comprising the sequence encoding human lactadherin as depicted in SEQ ID NO: 1 or at least amino acid residues 24-387 of said sequence, corresponding to the mature protein. Such

a sequence is represented on SEQ ID NO:2, for instance. Obviously, variants of said sequence can also be used as the starting material. Such a construct, generally a plasmid, is replicated in a competent host cell, in order to produce suitable quantities of nucleic acid. The nucleic acid is then treated in order to  
5 render non-functional the integrin binding site of lactadherin for which it codes. In this respect, the integrin binding site lies essentially in the N-terminal part of the protein, more particularly in the amino acid residues Arg Gly Asp at position 46-48 of SEQ ID NO:1.

In a particular example, the nucleic acid is treated by deletion of all or  
10 part of the sequence encoding amino acid residues 1 to 100 of SEQ ID NO:1, said deletion rendering the protein incapable of binding integrin  $\alpha\text{v}\beta 5$ . Even more preferably, the nucleic acid is treated by deletion of all or part of the sequence encoding amino acid residues 1 to 100 of SEQ ID NO: 1, said deletion comprising at least all or part of the sequence encoding the amino  
15 acid residues Arg Gly Asp at position 46-48 of SEQ ID NO:1. Preferred examples of variants comprise a deletion of amino acid residues 46-48, 45-49, 40-50 or 35-55 of SEQ ID NO:1, optionally in combination with a deletion of the amino acid residues 1-23 representing the secretion signal. The deletion can be performed by various means. In particular, the deletion is performed by  
20 treatment of the nucleic acid with a restriction enzyme which cleaves said nucleic acid in the appropriate region (including at artificially created restriction sites), optionally followed by digestion of the fragments with exonucleases and/or ligation of the resulting fragments.

In another particular example, the nucleic acid is treated by mutation(s)  
25 in all or part of the sequence encoding amino acid residues 1 to 100 of SEQ ID NO:1, said mutation(s) rendering the protein incapable of binding integrin  $\alpha\text{v}\beta 5$ . Even more preferably, the nucleic acid is treated by mutation(s) in all or part of the sequence encoding amino acid residues 1 to 100 of SEQ ID NO:1, said part comprising at least all or part of the sequence encoding the amino  
30 acid residues Arg Gly Asp at position 46-48 of SEQ ID NO:1. Preferred examples of variants comprise at least a mutation of one amino acid selected from the amino acid residues Arg Gly Asp at position 46-48 of SEQ ID NO:1. The mutation can be carried out by various means, including site-directed

mutagenesis, amplification with mutated primers, nucleic acid synthesis and cloning, etc. The mutation can lead to the suppression of one single amino acid residue or to its replacement by another conservative or non-conservative amino acid residue.

5           Once they are prepared, the structure of the nucleic acids is verified by digestion and/or sequencing. The resulting nucleic acids are then expressed in a host cell, for instance a bacteria, a yeast cell or a mammalian cell, and the variants thereby produced are recovered.

Particular variants of the present invention are:

- 10           - a protein comprising amino acid residues 49-387 of SEQ ID NO:1;  
            - a protein of SEQ ID NO:1 with a deletion of amino acid residues 46-48;  
            - a protein of SEQ ID NO:1 with a deletion of amino acid residues 1-23 and 46-48;  
            - a protein comprising amino acids 23-387 of SEQ ID NO:1 with a  
15           mutation in amino acid residue Arg at position 46;  
            - a protein comprising amino acids 23-387 of SEQ ID NO:1 with a mutation in amino acid residue Gly at position 47;  
            - a protein comprising amino acids 23-387 of SEQ ID NO:1 with a mutation in amino acid residue Asp at position 48;

20

5. Construction of a variant of human lactadherin lacking a functional Phosphatidyl serine binding site

25           This example discloses a method for the construction of variants of lactadherin lacking a functional Phosphatidyl Serine (PS) binding site. The variants obtained are essentially incapable of binding to PS and therefore do not efficiently bind particulate antigens, such as apoptotic bodies or vesicles. On the other hand, said variants advantageously retain the ability of lactadherin to bind dendritic cells, more particularly human dendritic cells,  
30           especially human immature dendritic cells. Accordingly, these molecules represent competitors of naturally-occurring lactadherin for the binding of dendritic cells thereby interfering with the development of an immune response, especially with the cross-priming of antigens. These variants can

also be used to deliver molecules to dendritic cells, in particular to facilitate (i.e., enhance) the uptake (e.g., the phagocytosis) of molecules by dendritic cells, in vitro, ex vivo or in vivo.

5 The variants of lactadherin lacking a functional PS binding site are constructed according to the following method.

A nucleic acid construct is provided comprising the sequence encoding human lactadherin as depicted in SEQ ID NO: 1, as disclosed in example 4. The nucleic acid is then treated in order to render non-functional the PS binding site of lactadherin for which it codes. In this respect, the PS binding  
10 site lies essentially in the C-terminal part of the protein, more particularly in the amino acid residues 242 to 387 of SEQ ID NO:1, even more preferably in the amino acid residues 350-387 of SEQ ID NO:1.

In a particular example, the nucleic acid is treated by deletion of all or part of the sequence encoding amino acid residues 242 to 387 of SEQ ID  
15 NO:1, more preferably comprising at least the amino acid residues 360-387 of SEQ ID NO:1, said deletion rendering the protein incapable of binding PS. The deletion can be performed by various means. In particular, the deletion is performed by treatment of the nucleic acid with a restriction enzyme which cleaves said nucleic acid in the appropriate region (including at artificially  
20 created restriction sites), optionally followed by digestion of the fragments with exonucleases and/or ligation of the resulting fragments.

In another particular example, the nucleic acid is treated by mutation(s) in all or part of the sequence encoding amino acid residues 242 to 387 of SEQ  
ID NO:1, more preferably at least in the sequence encoding the amino acid.  
25 residues 360-387 of SEQ ID NO:1, said mutation(s) rendering the protein incapable of binding PS. The mutation can be carried out by various means, including site-directed mutagenesis, amplification with mutated primers, nucleic acid synthesis and cloning, etc.

Once they are prepared, the structure of the nucleic acids is verified. by  
30 digestion and/or sequencing. The resulting nucleic acids are then expressed in a host cell, for instance a bacteria, a yeast cell, an insect cell or a mammalian cell, and the variants thereby produced are recovered.

Particular variants of the present invention are:



- a protein comprising amino acid residues 1 to 242 of SEQ ID NO:1;
  - a protein comprising amino acid residues 24 to 242 of SEQ ID NO: 1;
  - a protein of SEQ ID NO:1 with a deletion of amino acid residues 360-387;
- 5           - a protein of SEQ ID NO:1 with a mutation in one or several amino acid residues of the sequence 360-387.

CLAIMS

1. The use of lactadherin or a variant thereof, for the preparation of a composition for regulating the immune response.

5           2. The use according to claim 1, for the inhibition of the cross-priming of antigens.

3. The use according to claim 2, of a variant of lactadherin lacking a functional phospholipid binding site and/or a functional integrin binding site.

10           4. The use according to claim 1, for the stimulation of the phagocytosis of antigens by dendritic cells.

15           5. The use according to claim 1, for the stimulation of the cross-priming of antigens.

6. The use of lactadherin or a variant thereof, for the preparation of a composition for the delivery of a molecule to a dendritic cell.

20           7. The use according to any one of the preceding claims, wherein the lactadherin or variant thereof is human lactadherin or a variant thereof.

8. A composition comprising lactadherin or a variant thereof in association with a molecule.

25           9. The composition of claim 8, wherein said molecule is covalently associated to the lactadherin or variant thereof.

10. The composition of claim 8, comprising a liposome.

30           11. An immunogenic composition comprising lactadherin or a variant thereof in association with an antigen.

12. A variant of lactadherin, wherein said variant lacks a functional phospholipid binding site and/or a functional integrin binding site.

5 13. A chimeric protein comprising lactadherin or a variant thereof fused to a polypeptide.

14. A nucleic acid encoding a protein as defined in claim 13.

10 15. A liposome comprising a recombinant lactadherin or variant thereof.

16. A composition comprising a variant of lactadherin according to claim 12 or a chimeric protein according to claim 13 or a liposome according to claim 15.

15 17. The composition of claim 11, wherein the antigen is a protein, polypeptide, peptide, virus or bacteria.

20 18. A recombinant virus expressing lactadherin as a surface molecule.

19. A recombinant cell expressing lactadherin as a surface molecule.

1/5




FIGURE 1

2/5




FIGURE 2

3/5




FIGURE 3

4/5




FIGURE 4

5/5




FIGURE 5



## SEQUENCE LISTING

<110> INSERM  
INSTITUT CURIE  
CNRS

<120> Compositions and Methods using Lactadherin or Variants thereof

<130> Lactadherin

<140>

<141>

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 1934

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (61)..(1224)

<400> 1

agaaccccgcc ggggtctgag cagcccagcg tgcccatgcc agcgcccgcg tccccgcagc 60

atg	ccg	cgc	ccc	cgc	ctg	ctg	gcc	gcg	ctg	tgc	ggc	gcg	ctg	ctc	tgc	108
Met	Pro	Arg	Pro	Arg	Leu	Leu	Ala	Ala	Leu	Cys	Gly	Ala	Leu	Leu	Cys	
1				5					10					15		

gcc	ccc	agc	ctc	ctc	gtc	gcc	ctg	gat	atc	tgt	tcc	aaa	aac	ccc	tgc	156
Ala	Pro	Ser	Leu	Leu	Val	Ala	Leu	Asp	Ile	Cys	Ser	Lys	Asn	Pro	Cys	
			20					25					30			

cac	aac	ggt	ggt	tta	tgc	gag	gag	att	tcc	caa	gaa	gtg	cga	gga	gat	204
His	Asn	Gly	Gly	Leu	Cys	Glu	Glu	Ile	Ser	Gln	Glu	Val	Arg	Gly	Asp	
		35				40						45				

gtc	ttc	ccc	tcg	tac	acc	tgc	acg	tgc	ctt	aag	ggc	tac	gcg	ggc	aac	252
Val	Phe	Pro	Ser	Tyr	Thr	Cys	Thr	Cys	Leu	Lys	Gly	Tyr	Ala	Gly	Asn	
	50					55					60					

cac	tgt	gag	acg	aaa	tgt	gtc	gag	cca	ctg	ggc	atg	gag	aat	ggg	aac	300
His	Cys	Glu	Thr	Lys	Cys	Val	Glu	Pro	Leu	Gly	Met	Glu	Asn	Gly	Asn	

65	70	75	80	
att gcc aac tca cag atc gcc gcc tca tct gtg cgt gtg acc ttc ttg				348
Ile Ala Asn Ser Gln Ile Ala Ala Ser Ser Val Arg Val Thr Phe Leu				
	85	90	95	
ggt ttg cag cat tgg gtc ccg gag ctg gcc cgc ctg aac cgc gca ggc				396
Gly Leu Gln His Trp Val Pro Glu Leu Ala Arg Leu Asn Arg Ala Gly				
	100	105	110	
atg gtc aat gcc tgg aca ccc agc agc aat gac gat aac ccc tgg atc				444
Met Val Asn Ala Trp Thr Pro Ser Ser Asn Asp Asp Asn Pro Trp Ile				
	115	120	125	
cag gtg aac ctg ctg cgg agg atg tgg gta aca ggt gtg gtg acg cag				492
Gln Val Asn Leu Leu Arg Arg Met Trp Val Thr Gly Val Val Thr Gln				
	130	135	140	
ggt gcc agc cgc ttg gcc agt cat gag tac ctg aag gcc ttc aag gtg				540
Gly Ala Ser Arg Leu Ala Ser His Glu Tyr Leu Lys Ala Phe Lys Val				
	145	150	155	160
gcc tac agc ctt aat gga cac gaa ttc gat ttc atc cat gat gtt aat				588
Ala Tyr Ser Leu Asn Gly His Glu Phe Asp Phe Ile His Asp Val Asn				
	165	170	175	
aaa aaa cac aag gag ttt gtg ggt aac tgg aac aaa aac gcg gtg cat				636
Lys Lys His Lys Glu Phe Val Gly Asn Trp Asn Lys Asn Ala Val His				
	180	185	190	
gtc aac ctg ttt gag acc cct gtg gag gct cag tac gtg aga ttg tac				684
Val Asn Leu Phe Glu Thr Pro Val Glu Ala Gln Tyr Val Arg Leu Tyr				
	195	200	205	
ccc acg agc tgc cac acg gcc tgc act ctg cgc ttt gag cta ctg ggc				732
Pro Thr Ser Cys His Thr Ala Cys Thr Leu Arg Phe Glu Leu Leu Gly				
	210	215	220	
tgt gag ctg aac gga tgc gcc aat ccc ctg ggc ctg aag aat aac agc				780
Cys Glu Leu Asn Gly Cys Ala Asn Pro Leu Gly Leu Lys Asn Asn Ser				
	225	230	235	240
atc cct gac aag cag atc acg gcc tcc agc agc tac aag acc tgg ggc				828
Ile Pro Asp Lys Gln Ile Thr Ala Ser Ser Ser Tyr Lys Thr Trp Gly				
	245	250	255	
ttg cat ctc ttc agc tgg aac ccc tcc tat gca cgg ctg gac aag cag				876
Leu His Leu Phe Ser Trp Asn Pro Ser Tyr Ala Arg Leu Asp Lys Gln				

260	265	270	
ggc aac ttc aac gcc tgg gtt gcg ggg agc tac ggt aac gat cag tgg			924
Gly Asn Phe Asn Ala Trp Val Ala Gly Ser Tyr Gly Asn Asp Gln Trp			
275	280	285	
ctg cag gtg gac ctg ggc tcc tcg aag gag gtg aca ggc atc atc acc			972
Leu Gln Val Asp Leu Gly Ser Ser Lys Glu Val Thr Gly Ile Ile Thr			
290	295	300	
cag ggg gcc cgt aac ttt ggc tct gtc cag ttt gtg gca tcc tac aag			1020
Gln Gly Ala Arg Asn Phe Gly Ser Val Gln Phe Val Ala Ser Tyr Lys			
305	310	315	320
gtt gcc tac agt aat gac agt gcg aac tgg act gag tac cag gac ccc			1068
Val Ala Tyr Ser Asn Asp Ser Ala Asn Trp Thr Glu Tyr Gln Asp Pro			
325	330	335	
agg act ggc agc agt aag atc ttc cct ggc aac tgg gac aac cac tcc			1116
Arg Thr Gly Ser Ser Lys Ile Phe Pro Gly Asn Trp Asp Asn His Ser			
340	345	350	
cac aag aag aac ttg ttt gag acg ccc atc ctg gct cgc tat gtg cgc			1164
His Lys Lys Asn Leu Phe Glu Thr Pro Ile Leu Ala Arg Tyr Val Arg			
355	360	365	
atc ctg cct gta gcc tgg cac aac cgc atc gcc ctg cgc ctg gag ctg			1212
Ile Leu Pro Val Ala Trp His Asn Arg Ile Ala Leu Arg Leu Glu Leu			
370	375	380	
ctg ggc tgt tag tggccacctg ccacccccag gtcttctctgc ttcccatggg			1264
Leu Gly Cys			
385			
cccgtgcct ctgggttct cagccccctt aaatcaccat agggctgggg actggggaag			1324
gggaggggtgt tcagaggcag caccaccaca cagtcacccc tccctccctc ttcccccacc			1384
tccacctctc acgggcctg cccagcccc taagccccgt cccctaacct ccagtcctca			1444
ctgtctgtt ttcttaggca ctgagggatc tgagtaggtc tgggatggac aggaaagggc			1504
aaagtagggc gtgtggtttc cctgccccctg tccggaccgc cgatcccagg tgcgtgtgtc			1564
tctgtctctc ctageccctc tctcacacat cacattccca tgggtggcctc aagaaaggcc			1624
cggaagcccc aggctggaga taacagcctc ttgcccgctg gccctgcgtc ggccctgggg			1684

taccatgtgc cacaactgct gtggccccct gtccccaaga cacttcccct tgttcccctg 1744  
 gttgcctctc ttgccccttg tcctgaagcc cagcgacaca gaagggggtg gggcggtctc 1804  
 atggggagaaa agggagcgag gtcagaggag ccggcatggg ttggcagggt gggcgtttgg 1864  
 ggccctcatg ctggcttttc accccagagg acacaggcag cttccaaaat atatttatct 1924  
 tcttcacggg 1934

&lt;210&gt; 2

&lt;211&gt; 387

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met	Pro	Arg	Pro	Arg	Leu	Leu	Ala	Ala	Leu	Cys	Gly	Ala	Leu	Leu	Cys	1	5	10	15
Ala	Pro	Ser	Leu	Leu	Val	Ala	Leu	Asp	Ile	Cys	Ser	Lys	Asn	Pro	Cys	20	25	30	
His	Asn	Gly	Gly	Leu	Cys	Glu	Glu	Ile	Ser	Gln	Glu	Val	Arg	Gly	Asp	35	40	45	
Val	Phe	Pro	Ser	Tyr	Thr	Cys	Thr	Cys	Leu	Lys	Gly	Tyr	Ala	Gly	Asn	50	55	60	
His	Cys	Glu	Thr	Lys	Cys	Val	Glu	Pro	Leu	Gly	Met	Glu	Asn	Gly	Asn	65	70	75	80
Ile	Ala	Asn	Ser	Gln	Ile	Ala	Ala	Ser	Ser	Val	Arg	Val	Thr	Phe	Leu	85	90	95	
Gly	Leu	Gln	His	Trp	Val	Pro	Glu	Leu	Ala	Arg	Leu	Asn	Arg	Ala	Gly	100	105	110	
Met	Val	Asn	Ala	Trp	Thr	Pro	Ser	Ser	Asn	Asp	Asp	Asn	Pro	Trp	Ile	115	120	125	
Gln	Val	Asn	Leu	Leu	Arg	Arg	Met	Trp	Val	Thr	Gly	Val	Val	Thr	Gln	130	135	140	
Gly	Ala	Ser	Arg	Leu	Ala	Ser	His	Glu	Tyr	Leu	Lys	Ala	Phe	Lys	Val	145	150	155	160
Ala	Tyr	Ser	Leu	Asn	Gly	His	Glu	Phe	Asp	Phe	Ile	His	Asp	Val	Asn	165	170	175	
Lys	Lys	His	Lys	Glu	Phe	Val	Gly	Asn	Trp	Asn	Lys	Asn	Ala	Val	His	180	185	190	
Val	Asn	Leu	Phe	Glu	Thr	Pro	Val	Glu	Ala	Gln	Tyr	Val	Arg	Leu	Tyr	195	200	205	
Pro	Thr	Ser	Cys	His	Thr	Ala	Cys	Thr	Leu	Arg	Phe	Glu	Leu	Leu	Gly	210	215	220	
Cys	Glu	Leu	Asn	Gly	Cys	Ala	Asn	Pro	Leu	Gly	Leu	Lys	Asn	Asn	Ser	225	230	235	240
Ile	Pro	Asp	Lys	Gln	Ile	Thr	Ala	Ser	Ser	Ser	Tyr	Lys	Thr	Trp	Gly				



gaa ggc ttc aca ggc ctt gtg tgc aat gag act gag aga gga cca tgc	249
Glu Gly Phe Thr Gly Leu Val Cys Asn Glu Thr Glu Arg Gly Pro Cys	
55 60 65	
tcc cca aac cct tgc tac aat gat gcc aaa tgt ctg gtg act ttg gac	297
Ser Pro Asn Pro Cys Tyr Asn Asp Ala Lys Cys Leu Val Thr Leu Asp	
70 75 80	
aca cag cgt ggg gac atc ttc acc gaa tac atc tgc cag tgc cct gtg	345
Thr Gln Arg Gly Asp Ile Phe Thr Glu Tyr Ile Cys Gln Cys Pro Val	
85 90 95 100	
ggc tac tcg ggc atc cac tgt gaa acc gag acc aac tac tac aac ctg	393
Gly Tyr Ser Gly Ile His Cys Glu Thr Glu Thr Asn Tyr Tyr Asn Leu	
105 110 115	
gat gga gaa tac atg ttc acc aca gcc gtc ccc aat act gcc gtc ccc	441
Asp Gly Glu Tyr Met Phe Thr Thr Ala Val Pro Asn Thr Ala Val Pro	
120 125 130	
acc ccg gcc ccc acc ccc gat ctt tcc aac aac cta gcc tcc cgt tgt	489
Thr Pro Ala Pro Thr Pro Asp Leu Ser Asn Asn Leu Ala Ser Arg Cys	
135 140 145	
tct aca cag ctg ggc atg gaa ggg ggc gcc att gct gat tca cag att	537
Ser Thr Gln Leu Gly Met Glu Gly Gly Ala Ile Ala Asp Ser Gln Ile	
150 155 160	
tcc gcc tcg tat gtg tat atg ggt ttc atg ggc ttg cag cgc tgg ggc	585
Ser Ala Ser Tyr Val Tyr Met Gly Phe Met Gly Leu Gln Arg Trp Gly	
165 170 175 180	
ccg gag ctg gct cgt ctg tac cgc aca ggg atc gtc aat gcc tgg cac	633
Pro Glu Leu Ala Arg Leu Tyr Arg Thr Gly Ile Val Asn Ala Trp His	
185 190 195	
gcc agc aac tat gat agc aag ccc tgg atc cag gtg aac ctt ctg cgg	681
Ala Ser Asn Tyr Asp Ser Lys Pro Trp Ile Gln Val Asn Leu Leu Arg	
200 205 210	
aag atg cgg gta tca ggt gtg atg acg cag ggt gcc agc cgt gcc ggg	729
Lys Met Arg Val Ser Gly Val Met Thr Gln Gly Ala Ser Arg Ala Gly	
215 220 225	
agg gcg gag tac ctg aag acc ttc aag gtg gct tac agc ctc gac gga	777
Arg Ala Glu Tyr Leu Lys Thr Phe Lys Val Ala Tyr Ser Leu Asp Gly	
230 235 240	

**PCT/EP99/09036**

7

ccc ttc atg gct cgc tac gtg cgt gtc ctt cca gtg tcc tgg cat aac 1401  
 Pro Phe Met Ala Arg Tyr Val Arg Val Leu Pro Val Ser Trp His Asn  
 440 445 450

cgc atc acc ctg cgc ctg gag ctg ctg ggc tgt taatgctcag tcttgccagc 1454  
 Arg Ile Thr Leu Arg Leu Glu Leu Leu Gly Cys  
 455 460

ccaaacgatg aggatggcca gaggctgagg ggcctcctgg cctgcctcc caggccctgc 1514

tgccttctgt ggctgacgac cttctcggcc ttccctcctg attgtactgg ggctggaggc 1574

aggaagggcc aggggatttc agagttgccc ttcacccttt ccctcaccct gcagccccc 1634

caggcctcct gctagccccc ttctctcagg cattctgggg gagttggaca ggtctgagat 1694

gaatagagaa gaagagtga gttgggggtat gtgggctatc tgtaccaacc accccaagtc 1754

ctaaacttcc tgccagggtc tgactcagga ctgaaggag cccctgactg cccatccctc 1814

tctgcacacc acacattcct ccatgttcca ttccgggaag gagaggcca cgtccgcttg 1874

ctgtcccttg ggtcaccagg tctgcctcc tatctcctga gacgcctctt gacccttgca 1934

ctggagcctc agttgacaag gagactggcg ggtctggaga ggtcgggtggc tctgggtggt 1994

tgacaggttg gctgtgggac ctctgctggc ttgctacca agttaacaag cagattccaa 2054

aatacattcg tgttctccac tgg 2077

<210> 4

<211> 463

<212> PRT

<213> mammalian

<400> 4

Met Gln Val Ser Arg Val Leu Ala Ala Leu Cys Gly Met Leu Leu Cys  
 1 5 10 15

Ala Ser Gly Leu Phe Ala Ala Ser Gly Asp Phe Cys Asp Ser Ser Leu  
 20 25 30

Cys Leu Asn Gly Gly Thr Cys Leu Thr Gly Gln Asp Asn Asp Ile Tyr  
 35 40 45

Cys Leu Cys Pro Glu Gly Phe Thr Gly Leu Val Cys Asn Glu Thr Glu  
 50 55 60



Arg	Gly	Pro	Cys	Ser	Pro	Asn	Pro	Cys	Tyr	Asn	Asp	Ala	Lys	Cys	Leu	65	70	75	80
Val	Thr	Leu	Asp	Thr	Gln	Arg	Gly	Asp	Ile	Phe	Thr	Glu	Tyr	Ile	Cys	85	90	95	
Gln	Cys	Pro	Val	Gly	Tyr	Ser	Gly	Ile	His	Cys	Glu	Thr	Glu	Thr	Asn	100	105	110	
Tyr	Tyr	Asn	Leu	Asp	Gly	Glu	Tyr	Met	Phe	Thr	Thr	Ala	Val	Pro	Asn	115	120	125	
Thr	Ala	Val	Pro	Thr	Pro	Ala	Pro	Thr	Pro	Asp	Leu	Ser	Asn	Asn	Leu	130	135	140	
Ala	Ser	Arg	Cys	Ser	Thr	Gln	Leu	Gly	Met	Glu	Gly	Gly	Ala	Ile	Ala	145	150	155	160
Asp	Ser	Gln	Ile	Ser	Ala	Ser	Tyr	Val	Tyr	Met	Gly	Phe	Met	Gly	Leu	165	170	175	
Gln	Arg	Trp	Gly	Pro	Glu	Leu	Ala	Arg	Leu	Tyr	Arg	Thr	Gly	Ile	Val	180	185	190	
Asn	Ala	Trp	His	Ala	Ser	Asn	Tyr	Asp	Ser	Lys	Pro	Trp	Ile	Gln	Val	195	200	205	
Asn	Leu	Leu	Arg	Lys	Met	Arg	Val	Ser	Gly	Val	Met	Thr	Gln	Gly	Ala	210	215	220	
Ser	Arg	Ala	Gly	Arg	Ala	Glu	Tyr	Leu	Lys	Thr	Phe	Lys	Val	Ala	Tyr	225	230	235	240
Ser	Leu	Asp	Gly	Arg	Lys	Phe	Glu	Phe	Ile	Gln	Asp	Glu	Ser	Gly	Gly	245	250	255	
Asp	Lys	Glu	Phe	Leu	Gly	Asn	Leu	Asp	Asn	Asn	Ser	Leu	Lys	Val	Asn	260	265	270	
Met	Phe	Asn	Pro	Thr	Leu	Glu	Ala	Gln	Tyr	Ile	Arg	Leu	Tyr	Pro	Val	275	280	285	
Ser	Cys	His	Arg	Gly	Cys	Thr	Leu	Arg	Phe	Glu	Leu	Leu	Gly	Cys	Glu	290	295	300	
Leu	His	Gly	Cys	Leu	Glu	Pro	Leu	Gly	Leu	Lys	Asn	Asn	Thr	Ile	Pro	305	310	315	320

Asp Ser Gln Met Ser Ala Ser Ser Ser Tyr Lys Thr Trp Asn Leu Arg  
 325 330 335

Ala Phe Gly Trp Tyr Pro His Leu Gly Arg Leu Asp Asn Gln Gly Lys  
 340 345 350

Ile Asn Ala Trp Thr Ala Gln Ser Asn Ser Ala Lys Glu Trp Leu Gln  
 355 360 365

Val Asp Leu Gly Thr Gln Arg Gln Val Thr Gly Ile Ile Thr Gln Gly  
 370 375 380

Ala Arg Asp Phe Gly His Ile Gln Tyr Val Glu Ser Tyr Lys Val Ala  
 385 390 395 400

His Ser Asp Asp Gly Val Gln Trp Thr Val Tyr Glu Glu Gln Gly Ser  
 405 410 415

Ser Lys Val Phe Gln Gly Asn Leu Asp Asn Asn Ser His Lys Lys Asn  
 420 425 430

Ile Phe Glu Lys Pro Phe Met Ala Arg Tyr Val Arg Val Leu Pro Val  
 435 440 445

Ser Trp His Asn Arg Ile Thr Leu Arg Leu Glu Leu Leu Gly Cys  
 450 455 460

<210> 5

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 5

atgctactct gcgcctctg

19

<210> 6

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

WO 00/30667

PCT/EP99/09036

<223> Description of Artificial Sequence:oligonucleotide

<400> 6

gtcttgtagc tgctggagg

19